| Title |
Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines
|
|---|---|
| Published in |
Clinical Pharmacology : Advances and Applications, March 2013
|
| DOI | 10.2147/cpaa.s37582 |
| Pubmed ID | |
| Authors |
Sophie Peacock, Welf Prager |
| Abstract |
This review examines the pharmacologic and clinical characteristics of incobotulinumtoxinA (Xeomin(®)/Xeomeen(®)/Bocouture(®)/XEOMIN Cosmetic™; botulinum toxin type A [150 kDa]), which is free from complexing proteins, and discusses its efficacy and safety in the treatment of glabellar frown lines. Differences between incobotulinumtoxinA and other commercially available botulinum neurotoxin type A (BoNT/A) products that have been approved by the European Medicines Agency, US Food and Drug Administration, and other regulatory agencies for this indication are also discussed. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 25% |
| Switzerland | 1 | 25% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
| Scientists | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 22 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 5 | 23% |
| Researcher | 4 | 18% |
| Student > Doctoral Student | 3 | 14% |
| Librarian | 2 | 9% |
| Professor | 1 | 5% |
| Other | 3 | 14% |
| Unknown | 4 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 59% |
| Agricultural and Biological Sciences | 2 | 9% |
| Biochemistry, Genetics and Molecular Biology | 1 | 5% |
| Computer Science | 1 | 5% |
| Engineering | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 4 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 April 2024.
All research outputs
#6,561,838
of 25,584,565 outputs
Outputs from Clinical Pharmacology : Advances and Applications
#60
of 179 outputs
Outputs of similar age
#51,274
of 206,591 outputs
Outputs of similar age from Clinical Pharmacology : Advances and Applications
#2
of 6 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 179 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,591 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.